Professor Thomas Helleday's TEDx talk in Göteborg coming up soon...
We proudly present a completely novel way of treating cancer, which has been published in Nature.
The new concept is that cancer cells are killed by their own high level of intrinsic oxidative stress, not present in normal cells. We target the MTH1 protein required to prevent oxidative stress in cancer to become DNA damage. Normal cells have low level of oxidative stress and don’t need the MTH1 protein. See how the concept works!
The Helleday Laboratory was previously based at Oxford and Stockholm University and is currently located at the Science for Life Laboratory (Karolinska Institute).
We are raising funds to bring the MTH1 concept to cancer patients.
Help us to achieve this goal!
This progress bar will be updated weekly with your donations
Contact us if you prefer to donate funds directly to the Foundation's bank account or you can use Bankgiro: 548-0082
We have determined, together with colleagues at Stockholm University, for the first time a high-resolution 3D structure of the MTH1 protein using a X-ray crystallography technique. Here we can see the MTH1 inhibitor TH287 bound inside the active site of the protein.
Laser calligraphy with cells can be fun!
PARP inhibitors have been recently approved for the treatment of ovarian cancers in women with BRCA mutations.
The Helleday Laboratory discovered this novel way of killing cancer in 2005 and after successful clinical trials, Lynparza (olaparib) has been granted market authorization.
150,000 women in the European Union suffer from ovarian cancer and many of these patients will benefit from this new therapy.
We are working hard to improve the drug candidates and hope to be able to test in patients next year. Unfortunately, we are not allowed to test in patients today. Sign up for our newsletter to get updates.
Here you can read our previous newsletters.
Professor Thomas Helleday talks with the Swedish television channel SVT about the new approach to tackle cancer.
A successful case: Marie had her third relapse of ovarian cancer and contacted Thomas Helleday after she had heard about the PARP inhibitor treatment. She was entered into the trial and the cancer was eradicated.
"Naturally, I am extremely happy and impressed by your work. There are of course not enough words to describe how grateful I am, both for myself and for my children and family's sake. It gives real hope of breaking the chain of cancer in the family. I hope that it will soon appear on the market so that more can be helped by it."